PDZK1 functions as a regulator of HER2 stability and may serve as a potential biomarker and therapeutic target in HER2-positive breast cancer. Pharmacological upregulation of PDZK1 may represent a promising combinatorial therapeutic strategy for overcoming therapeutic resistance in breast cancer.

Moreover, functional rescue experiments with the PI3K activator 740 Y-P successfully reversed the hippeastrine-induced suppression of cell viability and PI3K/Akt phosphorylation. These findings indicate that hippeastrine exerts anti-OSCC effects by targeting the HSP90/PI3K/Akt/mTOR pathway, highlighting it as a novel therapeutic agent against OSCC.

Here we present results of a combination therapy employing two HSP90 inhibitors (AUY-922 or 17-AAG) and NPS to ablate cancer growth...Furthermore, HI and NPS, when combined, were used in lower doses than those required to achieve similar results, thus reducing the risk of potential side effects. By acting synergistically, combination therapy with HSP90 Inhibitors and NanoPulse Stimulation acts through distinct mechanisms, demonstrating a potent treatment that results in synergistic tumor mass reduction.

Rescue experiments were conducted using the HSP90AA1 inhibitor tanespimycin...Importantly, its elevated expression correlates with advanced clinical stage, specific molecular subtypes, and poor prognosis in BC patients. Our research results revealed an unrecognized regulatory axis, in which hsa_circ_0000520 facilitates BC cells progression by coordinating with HSP90AA1, highlighting hsa_circ_0000520 could be a promising diagnostic indicator and potential treatment target for BC.

Notably, our computational analysis based on GDSC's pRRophetic algorithm suggests that LCL161 and UMI-77 may be more effective in the low-risk group, while sapitinib and luminespib show potential efficacy in the high-risk group. In conclusion, our study indicates this model holds high promise as a reliable biomarker for outcome prediction and precision-medicine stratification in chRCC patients.

These findings support that nanoparticle reformulation can decouple antitumor efficacy from tissue-specific toxicity. FLIM02 suggests potential to reduce ocular toxicity while preserving antitumor activity, meriting further mechanistic studies and longitudinal preclinical models.

CCNJL has the potential to act as a valuable prognostic indicator and immunotherapy target in CHOL. Its expression pattern and associations with clinical outcomes, immune characteristics, and drug sensitivity highlight its potential for improving diagnostic and therapeutic approaches. Future research should focus on elucidating the underlying mechanisms and validating these findings in larger cohorts.

In vivo, onalespib remodels the tumor immune microenvironment, promotes CD8+ effector T-cell infiltration, and enhances the antitumor efficacy of cisplatin without compromising tolerability. Collectively, these findings define a functional HSP90-IDO1 regulatory axis and provide a mechanistic rationale for combination strategies targeting metabolic immune tolerance.

Several HSP90 inhibitors are in use or late-stage trials: pimitespib is approved in Japan for intestinal tumors, hypericin sodium under US regulatory review, and WP-1303 in Phase III development...Clinical evaluation confirmed translational potential, enabling tumor delineation and high-contrast imaging (SUVmax ∼ 5). This probe supports comprehensive cancer management and may guide clinical application of emerging HSP90 inhibitors.

This study highlights the prognostic relevance of MRGs in BLCA. The nine-gene signature may serve as a useful framework for risk stratification in BLCA, while the identified risk genes and candidate compounds provide a basis for further biological and experimental investigation rather than direct therapeutic inference.

Consistent with these in silico findings, exposure of mice to 24 μg/kg TCDF significantly increased the expression of Mmp7 and Hsp90aa1 in murine colonic tissues, increased the levels of proinflammatory cytokines Ifn-γ, Il-1β, and Il-6, and downregulated the expression of Mucin 2 (MUC2). Connectivity Map analysis based on the PCDD/F-related gene signature identified five candidate compounds targeting MMP7 and HSP90AA1, of which four HSP90 inhibitors (tanespimycin, alvespimycin, NVP-AUY922 and AT-13387) showed negative connectivity scores, suggesting potential to reverse the pollutant-induced expression profile.

Accordingly, the combination of ganetespib (an HSP90 inhibitor) and temsirolimus (a FDA approved-mTOR inhibitor) with cisplatin synergistically reduced colony formation and microtissues cell growth in vitro by increasing DNA-damage and apoptosis and in vivo enhancing mouse survival. Notably, all these data were confirmed also in Pt-resistant Non Small Cell Lung Cancer models. Collectively, our findings identify a promising new antitumor strategy for the treatment of Pt-resistance in cancer patients.